Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Receivables
kr6.2B
CAGR 3-Years
36%
CAGR 5-Years
48%
CAGR 10-Years
52%
Zealand Pharma A/S
CSE:ZEAL
Total Receivables
kr245.5m
CAGR 3-Years
28%
CAGR 5-Years
77%
CAGR 10-Years
25%
Ascendis Pharma A/S
NASDAQ:ASND
Total Receivables
€80.7m
CAGR 3-Years
90%
CAGR 5-Years
99%
CAGR 10-Years
41%
B
Bavarian Nordic A/S
CSE:BAVA
Total Receivables
kr1.1B
CAGR 3-Years
44%
CAGR 5-Years
59%
CAGR 10-Years
25%
F
Fluoguide AS
STO:FLUO
Total Receivables
kr6.4m
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Receivables
kr13.4m
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
3%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Total Receivables?
Total Receivables
6.2B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Receivables amounts to 6.2B DKK.

What is Genmab A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
52%

Over the last year, the Total Receivables growth was 28%. The average annual Total Receivables growth rates for Genmab A/S have been 36% over the past three years , 48% over the past five years , and 52% over the past ten years .

Back to Top